Literature DB >> 29610291

The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.

Jessica Yang1, Omid Hamid2, Richard D Carvajal3.   

Abstract

The ability of uveal melanoma cells to enter and exit dormancy plays a fundamental role in the development of metastatic disease. Neddylation blockade is a promising strategy to prolong tumor dormancy via impaired angiogenesis and prevent the establishment of metastases via elimination of cancer stem-like cells. Clin Cancer Res; 24(15); 3477-9. ©2018 AACRSee related article by Jin et al., p. 3741. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2018        PMID： 29610291      PMCID： PMC6446562          DOI： 10.1158/1078-0432.CCR-18-0020

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Uveal melanoma: implications of tumor doubling time.

Authors:  A D Singh
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; Katie A Matatall; Zachary T Kneass; Michael D Onken; Ryan S Lee; Anne M Bowcock; J William Harbour
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

3.  Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.

Authors:  Yanli Jin; Ping Zhang; Yun Wang; Bei Jin; Jingfeng Zhou; Jing Zhang; Jingxuan Pan
Journal:  Clin Cancer Res       Date:  2017-12-12       Impact factor: 12.531

4.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Authors:  John Sarantopoulos; Geoffrey I Shapiro; Roger B Cohen; Jeffrey W Clark; John S Kauh; Glen J Weiss; James M Cleary; Devalingam Mahalingam; Michael D Pickard; Hélène M Faessel; Allison J Berger; Kristine Burke; George Mulligan; Bruce J Dezube; R Donald Harvey
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

5.  Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Authors:  Ronan T Swords; Harry P Erba; Daniel J DeAngelo; Dale L Bixby; Jessica K Altman; Michael Maris; Zhaowei Hua; Stephen J Blakemore; Hélène Faessel; Farhad Sedarati; Bruce J Dezube; Francis J Giles; Bruno C Medeiros
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

6.  Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy.

Authors:  Helen Kalirai; Bertil E Damato; Sarah E Coupland
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

7.  Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis.

Authors:  Shu-Hong Chang; Lori A Worley; Michael D Onken; J William Harbour
Journal:  Melanoma Res       Date:  2008-06       Impact factor: 3.599

8.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Authors:  Jatin J Shah; Andrzej J Jakubowiak; Owen A O'Connor; Robert Z Orlowski; R Donald Harvey; Mitchell R Smith; Daniel Lebovic; Catherine Diefenbach; Kevin Kelly; Zhaowei Hua; Allison J Berger; George Mulligan; Hélène M Faessel; Stephen Tirrell; Bruce J Dezube; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2015-11-11       Impact factor: 12.531

9.  Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Authors:  Ronan T Swords; Steven Coutre; Michael B Maris; Joshua F Zeidner; James M Foran; Jose Cruz; Harry P Erba; Jesus G Berdeja; Wayne Tam; Saran Vardhanabhuti; Iwona Pawlikowska-Dobler; Hélène M Faessel; Ajeeta B Dash; Farhad Sedarati; Bruce J Dezube; Douglas V Faller; Michael R Savona
Journal:  Blood       Date:  2018-01-18       Impact factor: 22.113

10.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

Authors:  Shailender Bhatia; Anna C Pavlick; Peter Boasberg; John A Thompson; George Mulligan; Michael D Pickard; Hélène Faessel; Bruce J Dezube; Omid Hamid
Journal:  Invest New Drugs       Date:  2016-04-08       Impact factor: 3.850
View more
  1 in total

1.  Flavokawain A Reduces Tumor-Initiating Properties and Stemness of Prostate Cancer.

Authors:  Liankun Song; Merci Mino; Jana Yamak; Vyvyan Nguyen; Derron Lopez; Victor Pham; Ali Fazelpour; Vinh Le; Dongjun Fu; Matthew Tippin; Edward Uchio; Xiaolin Zi
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.